Literature DB >> 28926287

Succeeding in Breaking the R-CHOP Ceiling in DLBCL: Learning From Negative Trials.

Andre Goy1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28926287     DOI： 10.1200/JCO.2017.74.7360

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Authors:  Nancy L Bartlett; Wyndham H Wilson; Sin-Ho Jung; Eric D Hsi; Matthew J Maurer; Levi D Pederson; Mei-Yin C Polley; Brandelyn N Pitcher; Bruce D Cheson; Brad S Kahl; Jonathan W Friedberg; Louis M Staudt; Nina D Wagner-Johnston; Kristie A Blum; Jeremy S Abramson; Nishitha M Reddy; Jane N Winter; Julie E Chang; Ajay K Gopal; Amy Chadburn; Susan Mathew; Richard I Fisher; Kristy L Richards; Heiko Schöder; Andrew D Zelenetz; John P Leonard
Journal:  J Clin Oncol       Date:  2019-04-02       Impact factor: 44.544

2.  Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

Authors:  Matthew J Maurer; Hervé Ghesquières; Brian K Link; Jean-Philippe Jais; Thomas M Habermann; Carrie A Thompson; Corinne Haioun; Cristine Allmer; Patrick B Johnston; Richard Delarue; Ivana N Micallef; Frederic Peyrade; David J Inwards; Nicolas Ketterer; Umar Farooq; Olivier Fitoussi; William R Macon; Thierry J Molina; Sergei Syrbu; Andrew L Feldman; Susan L Slager; George J Weiner; Stephen M Ansell; James R Cerhan; Gilles A Salles; Thomas E Witzig; Hervé Tilly; Grzegorz S Nowakowski
Journal:  J Clin Oncol       Date:  2018-04-19       Impact factor: 44.544

3.  Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis.

Authors:  Martin D Berger; Sven Trelle; Annina E Büchi; Sabrina Jegerlehner; Codruta Ionescu; Thierry Lamy de la Chapelle; Urban Novak
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

4.  Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma.

Authors:  Tian Zhang; Xu-Wen Guan; John G Gribben; Feng-Ting Liu; Li Jia
Journal:  Cell Death Dis       Date:  2019-04-15       Impact factor: 8.469

5.  Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.

Authors:  Xiao Yang; Dong Fang; Ming Li; Jiayi Chen; Yuanbo Cheng; Jianming Luo
Journal:  Med Sci Monit       Date:  2021-03-25

6.  A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL.

Authors:  Kohta Miyawaki; Koji Kato; Takeshi Sugio; Kensuke Sasaki; Hiroaki Miyoshi; Yuichiro Semba; Yoshikane Kikushige; Yasuo Mori; Yuya Kunisaki; Hiromi Iwasaki; Toshihiro Miyamoto; Frank C Kuo; Jon C Aster; Koichi Ohshima; Takahiro Maeda; Koichi Akashi
Journal:  Blood Adv       Date:  2022-04-12

7.  Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.

Authors:  Chiara Facciotto; Julia Casado; Laura Turunen; Suvi-Katri Leivonen; Manuela Tumiati; Ville Rantanen; Liisa Kauppi; Rainer Lehtonen; Sirpa Leppä; Krister Wennerberg; Sampsa Hautaniemi
Journal:  Clin Epigenetics       Date:  2019-12-11       Impact factor: 6.551

Review 8.  Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm.

Authors:  Jennifer L Crombie; Philippe Armand
Journal:  J Clin Oncol       Date:  2020-08-19       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.